Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...

Wegovy is the first drug in India approved for both weight management and risk reduction of major adverse cardiovascular ...

Stock markets have rallied after U.S. President Donald Trump announced a ceasefire in the Israel-Iran conflict, although the ...

U.S. stocks rallied and the price of oil tumbled Monday in hopes that Iran will not disrupt the global flow of crude, ...

Danish drugmaker Novo Nordisk officially launched its blockbuster weight-loss drug Wegovy on Tuesday as a once-a-week ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

The endocrinologist and researcher was one of several investigators who presented Phase 3 clinical trial results at the 85th Scientific Sessions of the American Diabetes Association for a long-lasting ...

The calming in the oil market came as several analysts said Iran would likely refrain from closing the waterway. Iran itself ...

Hims & Hers Health Inc.'s stock booked record losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly one-quarter of their body weight in early trials.